Sendoxan 50 mg Norge - norsk - Statens legemiddelverk

sendoxan 50 mg

baxter medical ab - syklofosfamidmonohydrat - tablett, filmdrasjert - 50 mg

Sendoxan 200 mg Norge - norsk - Statens legemiddelverk

sendoxan 200 mg

baxter medical ab - syklofosfamidmonohydrat - pulver til injeksjonsvæske, oppløsning - 200 mg

Sendoxan 500 mg Norge - norsk - Statens legemiddelverk

sendoxan 500 mg

baxter medical ab - syklofosfamidmonohydrat - pulver til injeksjonsvæske, oppløsning - 500 mg

Sendoxan 1000 mg Norge - norsk - Statens legemiddelverk

sendoxan 1000 mg

baxter medical ab - syklofosfamidmonohydrat - pulver til injeksjonsvæske, oppløsning - 1000 mg

Trecondi Den europeiske union - norsk - EMA (European Medicines Agency)

trecondi

medac gesellschaft für klinische spezialpräparate mbh - treosulfan - hematopoietisk stamcelletransplantasjon - antineoplastiske midler - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.

Takrolimus Accord 0.1 % Norge - norsk - Statens legemiddelverk

takrolimus accord 0.1 %

accord healthcare b.v. - takrolimusmonohydrat - salve - 0.1 %

Takrozem 0.1 % Norge - norsk - Statens legemiddelverk

takrozem 0.1 %

pierre fabre dermatologie - takrolimus - salve - 0.1 %

Accofil 30 mill E/0.5 ml Norge - norsk - Statens legemiddelverk

accofil 30 mill e/0.5 ml

2care4 aps - filgrastim - injeksjons-/infusjonsvæske, oppløsning i ferdigfylt sprøyte - 30 mill e/0.5 ml

Accofil 48 mill E/0.5 ml Norge - norsk - Statens legemiddelverk

accofil 48 mill e/0.5 ml

2care4 aps - filgrastim - injeksjons-/infusjonsvæske, oppløsning i ferdigfylt sprøyte - 48 mill e/0.5 ml

Zolsketil pegylated liposomal Den europeiske union - norsk - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.